Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
Ahmad HaidarVirginie MessierLaurent LegaultMartin LadouceurRémi Rabasa-LhoretPublished in: Diabetes, obesity & metabolism (2017)
The dual-hormone artificial pancreas had the lowest risk of hypoglycaemia, but the differences were not statistically significant. Larger studies are needed.